Navigation Links
Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
Date:9/3/2013

>On August 29, 2013, St. Jude Medical, Inc. (St. Jude Medical) announced that it has bagged the CE Mark approval for its EnligHTN Renal Denervation System which is used to treat patients with drug-resistant uncontrolled hypertension. According to the Company, the new system has an advanced generator that delivers simultaneous ablations through a multi-electrode catheter, which reduces total ablation time from c.24 minutes required by the first generation system to four minutes by the new system. Frank J. Callaghan, President of the St. Jude Medical Cardiovascular and Ablation Technologies Division, said, "The next generation EnligHTN system offers physicians our proven multi-electrode catheter with a new intuitive, faster generator that quickly and effectively delivers consistent ablations with a significant reduction in procedure time. These advancements deliver on our strategy to bring new innovations to a developing market to provide options for patients who currently do not have an adequate treatment for their uncontrolled drug-resistant hypertension." The Full Research Report on St. Jude Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/b338_STJ]

Community Health Systems Inc. Research Report

On August 22, 2013, Community Health Systems Inc. (CHS) and Cleveland Clinic announced that they have been selected for exclusive negotiations in relation to the purchase of certain assets of Akron General Health System. According to the Company, the assets include Akron General Medical Center - a 532-bed acute care hospital in Akron, Ohio; 70-bed Edwin Shaw Rehabilitation Hospital in Cuyahoga Falls, Ohio; Lodi Community Hospital - a 25-bed critical access hospital c
'/>"/>

SOURCE Analysts' Corner
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Arena Pharmaceuticals Completes Phase 1b Clinical Trial Evaluating APD811 for Pulmonary Arterial Hypertension
2. Magellan Diagnostics Receives FDA Clearance for LeadCare Ultra Bench-top Clinical Lead Analyzer
3. Cellular Biomedicine Group Announces Completion of Patient Enrollment for Phase I Clinical Trial for Liver Cancer
4. Selexys Pharmaceuticals Initiates SUSTAIN Phase 2 Clinical Trial in Sickle Cell Patients with Pain Crises
5. Final Patient Completes Prosonix Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
6. Ampio Pharmaceuticals, Inc. Announces Positive Results for Ampion in Osteoarthritis of the Knee Clinical Trial
7. Start-up Seeks Crowd Funding to Complete Clinical Studies Supporting Breakthrough Blood Test for Earlier Detection of Melanoma
8. MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development
9. Neuralstem Reports Second Quarter Financial Results And Provides Business And Clinical Update
10. Sanarias Malaria Vaccine Yields Unprecedented Protection In Phase 1 Clinical Trial
11. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 Antigen Discovery Inc. (ADi), a ... , announced the receipt of a National Institutes of ... from the National Institute of Dental and Craniofacial Research (NIDCR). ... a Pan-HIV Protein Microarray Chip, which will contain every ... and aid in the development of safe and effective ...
(Date:10/22/2014)... 22, 2014   Reproductive Medicine Associates of ... the field of infertility, presents new clinical research ... The research abstract, released during the 70 th ... meeting in Honolulu, Hawaii , ... defect (SGD) pre-implantation genetic diagnosis (PGD). ...
(Date:10/22/2014)... Oct. 22, 2014  Paper Pak Industries, a ... APLS ® Body Guard Bio, a disposable, ... of bacteria and virus while protecting service providers ... Bio features a rugged, external nylon shell, watertight ... a leak-proof inner chamber that contains contaminated and ...
Breaking Medicine Technology:Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2
... New Studies Highlight Potential Benefit of Unique ... -- Stimulant drug abuse,remains an ongoing concern ... treat Attention Deficit Hyperactivity Disorder,(ADHD). Data presented ... of,the American Psychiatric Association highlighted findings that,long-acting ...
... Austria, May 23, 2007-The chemotherapy drug,docetaxel currently offers ... the result of a now,published clinical trial that ... chemotherapy drugs. When using docetaxel, the risk of,disease ... when using the,next-best chemotherapy drug. , The use ...
Cached Medicine Technology:New Data Suggests Less Abuse-Related Effects For OROS,Methylphenidate 2New Data Suggests Less Abuse-Related Effects For OROS,Methylphenidate 3New Data Suggests Less Abuse-Related Effects For OROS,Methylphenidate 4New Data Suggests Less Abuse-Related Effects For OROS,Methylphenidate 5Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of,Docetaxel Chemotherapy 2Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of,Docetaxel Chemotherapy 3
(Date:10/22/2014)... Los Angeles, California (PRWEB) October 22, 2014 ... Recovery 2.0: Move Beyond Addiction and Upgrade Your Life (Paperback; ... the field of Yoga & Recovery. This book is ... and thrive in a life of recovery. , Recovery ... of the 12 Steps; Recovery 2.0 is a guide for ...
(Date:10/22/2014)... Best Cheap Hosting USA is among ... site has recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) ... from around the world. , “iPower is one of ... is providing various kinds of useful products for new ... offering excellent customer service and a number of features ...
(Date:10/22/2014)... Although there are only 24 hours in a day, ... have trouble finding time within their busy schedules for exercise and ... of time to get in shape. Here are five ways you ... , Change Up Your Commute , Consider riding a bike ... exercise into your daily routine. If you must use your car ...
(Date:10/22/2014)... WALTHAM, MA (PRWEB) October 22, 2014 ... developing new solutions for the treatment of bacterial infections, ... J. Sinskey has joined its board of directors. ... Microbiology and Engineering Systems at The Massachusetts Institute of ... the MIT faculty since 1968. Dr. Sinskey also holds ...
(Date:10/22/2014)... -- Two sisters in high school have developed ways ... Medha Krishen use electronic stethoscopes, which electronically amplify body ... patterns or heartbeats. Ilina, a senior at Port ... a way to detect early lung damage in people ... Ilina recorded one breath cycle each from 16 smokers, ...
Breaking Medicine News(10 mins):Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2
... risk of post-traumatic stress, study finds, , , THURSDAY, ... children in pediatric intensive care units experience delusions, and ... of developing post-traumatic stress syndrome after their hospital stay. ... to be sedated for more than two days, and ...
... Palomid 529 as an inhibitor of macular degeneration, diabetic ... ... Mass., May 1 Paloma Pharmaceuticals,Inc. today announced it has ... for Research in Vision and Ophthalmology (ARVO),describing the activity of ...
... CONSHOHOCKEN, Pa., May 1 Cadient Group, the,premier ... today it has appointed Barbara Dowling as Senior ... the healthcare,vertical on both the client and agency ... digital channel to address business critical,issues. In this ...
... 1 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS;,NASDAQ: DDSS) today ... 2008 results conference call and Annual Meeting of Shareholders., ... May 8 at 8:30 a.m. (ET) Labopharm will host ... results. Labopharm will,report its first quarter 2008 financial results ...
... N.Y., May 1 Gentiva Health,Services, Inc. (Nasdaq: GTIV ... reported the following financial,results for the first quarter ended March ... ), -- Net revenues increased 8% to $323.7 million ... 1, 2007. -- Net income increased 13% to $7.7 ...
... three children admitted to pediatric intensive care will experience ... for post-traumatic stress symptoms, according to a new study ... (PICU). , The study, which appears in the ... Respiratory and Critical Care Medicine, published by the American ...
Cached Medicine News:Health News:Delusions Common in Pediatric ICU 2Health News:Delusions Common in Pediatric ICU 3Health News:Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting 2Health News:Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting 3Health News:Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting 4Health News:Cadient Group Appoints Barbara Dowling to Senior Vice President Customer Engagements 2Health News:Labopharm announces details for first quarter results conference call and annual meeting 2Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 2Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 3Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 4Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 5Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 6Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 7Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 8Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 9Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 10Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 11Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 12Health News:Haunted by hallucinations: Children in the PICU traumatized by delusions 2
... Avaulta™ BioSynthetic Mesh is ... coated in the central ... hydrophilic film of porcine ... of the Avaulta™ BioSynthetic ...
Comprised of a monofilament polypropylene mesh coated with hydrophilic porcine collagen, Pelvitex™ mesh is clinically proven coating to enhance the healing process, along with the strength and d...
... is a soft monofilament ... be used for a ... procedures, including cystocele, rectocele, ... yet strong, POPmeshs flexibility ...
... Hydrix XM is a ... pericardium, a material known for ... sourcing and manufacturing procedures ensure ... safety. Caldera's patented processing enhances ...
Medicine Products: